Patents Assigned to ALARUM DEVELOPMENT LTD.
  • Patent number: 10478482
    Abstract: The present invention provides new immunological compositions and vaccines comprising selected M. tuberculosis antigens and antigenic peptides as well as nucleic acids encoding said antigens for use in the prevention, prophylaxis and treatment of mycobacterial infection, especially tuberculosis. In particular the invention provides recombinant BCG based vaccines in which one or more of the selected M. tuberculosis antigens are over expressed. The invention further provides isolated peptides for use in methods for diagnosing, characterizing, or classifying mycobacterial infections.
    Type: Grant
    Filed: February 26, 2019
    Date of Patent: November 19, 2019
    Assignee: ALARUM DEVELOPMENT LTD
    Inventor: Markus Maeurer
  • Publication number: 20190175715
    Abstract: The present invention provides new immunological compositions and vaccines comprising selected M. tuberculosis antigens and antigenic peptides as well as nucleic acids encoding said antigens for use in the prevention, prophylaxis and treatment of mycobacterial infection, especially tuberculosis. In particular the invention provides recombinant BCG based vaccines in which one or more of the selected M. tuberculosis antigens are over expressed. The invention further provides isolated peptides for use in methods for diagnosing, characterizing, or classifying mycobacterial infections.
    Type: Application
    Filed: February 26, 2019
    Publication date: June 13, 2019
    Applicant: ALARUM DEVELOPMENT LTD.
    Inventor: Markus Maeurer
  • Publication number: 20180064798
    Abstract: The present invention provides new immunological compositions and vaccines comprising selected M. tuberculosis antigens and antigenic peptides as well as nucleic acids encoding said antigens for use in the prevention, prophylaxis and treatment of mycobacterial infection, especially tuberculosis. In particular the invention provides recombinant BCG based vaccines in which one or more of the selected M. tuberculosis antigens are over expressed. The invention further provides isolated peptides for use in methods for diagnosing, characterizing, or classifying mycobacterial infections.
    Type: Application
    Filed: July 10, 2017
    Publication date: March 8, 2018
    Applicant: ALARUM DEVELOPMENT LTD.
    Inventor: Markus Maeurer
  • Publication number: 20140127251
    Abstract: The present invention provides new immunological compositions and vaccines comprising selected M. tuberculosis antigens and antigenic peptides as well as nucleic acids encoding said antigens for use in the prevention, prophylaxis and treatment of mycobacterial infection, especially tuberculosis. In particular the invention provides recombinant BCG based vaccines in which one or more of the selected M. tuberculosis antigens are over expressed. The invention further provides isolated peptides for use in methods for diagnosing, characterizing, or classifying mycobacterial infections.
    Type: Application
    Filed: April 11, 2012
    Publication date: May 8, 2014
    Applicant: ALARUM DEVELOPMENT LTD.
    Inventor: Markus Maeurer